U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Lanreotide is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analog of somatostatin. It is available in several countries, including the United Kingdom, Australia and Canada, and was approved for sale in the United States by the Food and Drug Administration on August 30, 2007. Lanreotide was developed in the lab of Dr. David H. Coy, School of Medicine. Dr. Coy serves as Director of the Peptide Laboratory. Lanreotide (as lanreotide acetate) is manufactured by Ipsen, and marketed under the trade name Somatuline. The mechanism of action of lanreotide is believed to be similar to that of natural somatostatin. Lanreotide has a high affinity for human somatostatin receptors (SSTR) 2 and 5 and a reduced binding affinity for human SSTR1, 3, and 4. Activity at human SSTR 2 and 5 is the primary mechanism believed responsible for GH inhibition. Like somatostatin, lanreotide is an inhibitor of various endocrine, neuroendocrine, exocrine and paracrine functions. Lanreotide inhibits the basal secretion of motilin, gastric inhibitory peptide and pancreatic polypeptide, but has no significant effect on the secretion of secretin. Lanreotide inhibits postprandial secretion of pancreatic polypeptide, gastrin and cholecystokinin (CCK). In healthy subjects, lanreotide produces a reduction and a delay in post-prandial insulin secretion, resulting in transient, mild glucose intolerance.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SOMATULINE DEPOT

Approved Use

Somatuline Depot (lanreotide) Injection 60 mg, 90 mg and 120 mg is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. The goal of treatment in acromegaly is to reduce growth hormone (GH) and insulin growth factor-1 (IGF-1) levels to normal. Somatuline Depot (lanreotide) Injection is a somatostatin analog indicated for: the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy (1)

Launch Date

1.18843205E12
PubMed

PubMed

TitleDatePubMed
Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
2001
[Therapy with somatostatin analogs in patient with orbitopathy and positive Octreoscan].
2001
Effectiveness of long-acting octreotide in suppressing hormonogenesis and tumor growth in thyrotropin-secreting pituitary adenomas: report of two cases.
2001 Aug
[Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].
2001 Aug
Serum levels of tumor necrosis factor-alpha, soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, and soluble interleukin-1 receptor antagonist in patients with thyroid eye disease undergoing treatment with somatostatin analogues.
2001 Dec
[Lanreotide acetate may cure cystic dystrophy in heterotopic pancreas of the duodenal wall].
2001 Dec
[Somatostatin analogues for the treatment of gastro-entero-pancreatic neuroendocrine tumours].
2001 Dec
Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands.
2001 Jul
[Preoperative administration of a slow releasing somatostatin analog (SR-lanreotide, BIM 23014) in patients with acromegaly in the course of GH-releasing adenoma].
2001 Mar-Apr
Technetium-99m direct radiolabeling of lanreotide: a somatostatin analog.
2001 Nov
[Therapy of pituitary diseases. What can be achieved with medication and hormones?].
2001 Nov 1
Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma.
2001 Oct
Effects of the somatostatin analogue octreotide on renal function in conscious diabetic rats.
2001 Oct
[Somatostatin and somatostatin receptors in the prostate].
2001 Sep
[Medical treatment of digestive neuroendocrine tumours].
2001 Sep
Somatostatin analogs and radiopeptides in cancer therapy.
2002
Carcinoid tumors--somatostatine in the diagnosis and therapy.
2002
Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
2002
Carcinoid of the pancreas.
2002
In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial.
2002 Apr
Varying additive effects of bromocriptine with two somatostatin analogs in cultures of GH-secreting adenomas.
2002 Aug
Management of thyroid eye disease.
2002 Aug
New approaches in targeting intracerebral tumours with 90Y-labelled radiopeptides.
2002 Dec
Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study.
2002 Dec
[Effect of lanreotide on prolactin level in patients with pituitary mixed tumors].
2002 Dec
Evaluation of lanreotide effects on human exocrine pancreatic secretion after a single dose: preliminary study.
2002 Feb
Absence of therapeutic efficacy of the somatostatin analogue lanreotide in advanced primary hepatic cholangiocellular cancer and adenocarcinoma of the gallbladder despite in vivo somatostatin-receptor expression.
2002 Feb
Drug design at peptide receptors: somatostatin receptor ligands.
2002 Feb-Apr
Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
2002 Jan
Somatostatin and somatostatin analogues: diagnostic and therapeutic uses.
2002 Jan
Lanreotide labeled with 99mTc: preparation, preclinical testing and comparison with (111)In-DTPA-octreotide.
2002 Jul-Aug
Effects of two different somatostatin analogs on glucose tolerance in acromegaly.
2002 Jun
Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly.
2002 Mar
Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues.
2002 Mar
Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly.
2002 Mar
Somatostatin analogs and prednisone in advanced refractory thymic tumors.
2002 Mar 1
The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?
2002 May
Labeling and quality control of 188Re-lanreotide.
2002 Nov
Radiolabeled peptides in the diagnosis and therapy of oncological diseases.
2002 Nov
Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves' disease.
2002 Nov
Somatostatin analogs in the treatment of medullary thyroid carcinoma.
2002 Oct
Serum leptin levels in acromegaly--a significant role for adipose tissue and fasting insulin/glucose ratio.
2002 Oct
[Current treatment of carcinoid tumor].
2002 Oct
Are somatostatin analogues (octreotide and lanreotide) effective in promoting healing of enterocutaneous fistulas?
2002 Sep
Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumours.
2002 Sep
Short-term suppression of GH and IGF-I levels improves gonadal function and sperm parameters in men with acromegaly.
2002 Sep
Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly.
2002 Sep
Somatostatin receptors (sst2) are coupled to Go and modulate GTPase activity in the rabbit retina.
2003 Feb
The effect of the somatostatin analogue lanreotide on the prevention of urethral strictures in a rabbit model.
2003 Mar
[The role of somatostatin analogues in the treatment of hypophyseal adenomas].
2003 Mar
Patents

Patents

Sample Use Guides

Patients should begin treatment with Somatuline Depot (lanreotide) 90 mg given via the deep subcutaneous route, at 4 week intervals for 3 months. After 3 months dosage may be adjusted as follows: • GH >1 to ≤ 2.5 ng/mL, IGF-1 normal and clinical symptoms controlled: maintain. Somatuline Depot dose at 90 mg every 4 weeks. • GH > 2.5 ng/mL, IGF-1 elevated and/or clinical symptoms uncontrolled, increase Somatuline Depot dose to 120 mg every 4 weeks. • GH ≤ 1 ng/mL, IGF-1 normal and clinical symptoms controlled: reduce Somatuline Depot dose to 60 mg every 4 weeks.
Route of Administration: Other
Treatment with lanreotide alone at doses of either 100 or 1000 nM for 48 h reduced clonogenic survival by 5–10%. Radiation alone produced a dose-dependent survival curve with a SF2 of 48–55%, and lanreotide had no effect on this curve. The addition of lanreotide resulted in a 23% increase in the proportion of apoptotic sub-G1 cells following irradiation.
Name Type Language
LANREOTIDE
INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
LANREOTIDE [WHO-DD]
Common Name English
LANREOTIDE [MI]
Common Name English
LANREOTIDE [INN]
Common Name English
L-THREONINAMIDE, 3-(2-NAPHTHALENYL)-D-ALANYL-L-CYSTEINYL-L-TYROSYL-D-TRYPTOPHYL-L-LYSYL-L-VALYL-L-CYSTEINYL-, CYCLIC (2->7)-DISULPHIDE
Common Name English
LANREOTIDE [VANDF]
Common Name English
3-(2-NAPHTHYL)-D-ALANYL-L-CYSTEINYL-L-TYROSYL-D-TRYPTOPHYL-L-LYSYL-L-VALYL-L-CYSTEINYL-L-THREONINAMIDE, CYCLIC (2->7)-DISULPHIDE
Common Name English
3-(2-NAPHTHYL)-D-ALANYL-L-CYSTEINYL-L-TYROSYL-D-TRYPTOPHYL-L-LYSYL-L-VALYL-L-CYSTEINYL-L-THREONINAMIDE, CYCLIC (2->7)-DISULFIDE
Common Name English
L-THREONINAMIDE, 3-(2-NAPHTHALENYL)-D-ALANYL-L-CYSTEINYL-L-TYROSYL-D-TRYPTOPHYL-L-LYSYL-L-VALYL-L-CYSTEINYL-, CYCLIC (2->7)-DISULFIDE
Common Name English
ANGIOPEPTIN
Common Name English
LANREOTIDE [MART.]
Common Name English
Classification Tree Code System Code
LIVERTOX 540
Created by admin on Mon Jun 28 00:59:11 UTC 2021 , Edited by admin on Mon Jun 28 00:59:11 UTC 2021
FDA ORPHAN DRUG 136300
Created by admin on Mon Jun 28 00:59:11 UTC 2021 , Edited by admin on Mon Jun 28 00:59:11 UTC 2021
WHO-VATC QH01CB03
Created by admin on Mon Jun 28 00:59:11 UTC 2021 , Edited by admin on Mon Jun 28 00:59:11 UTC 2021
NCI_THESAURUS C62799
Created by admin on Mon Jun 28 00:59:11 UTC 2021 , Edited by admin on Mon Jun 28 00:59:11 UTC 2021
NDF-RT N0000000194
Created by admin on Mon Jun 28 00:59:11 UTC 2021 , Edited by admin on Mon Jun 28 00:59:11 UTC 2021
WHO-ATC H01CB03
Created by admin on Mon Jun 28 00:59:11 UTC 2021 , Edited by admin on Mon Jun 28 00:59:11 UTC 2021
NDF-RT N0000175904
Created by admin on Mon Jun 28 00:59:11 UTC 2021 , Edited by admin on Mon Jun 28 00:59:11 UTC 2021
Code System Code Type Description
MESH
C060347
Created by admin on Mon Jun 28 00:59:11 UTC 2021 , Edited by admin on Mon Jun 28 00:59:11 UTC 2021
PRIMARY
WIKIPEDIA
LANREOTIDE
Created by admin on Mon Jun 28 00:59:11 UTC 2021 , Edited by admin on Mon Jun 28 00:59:11 UTC 2021
PRIMARY
RXCUI
68092
Created by admin on Mon Jun 28 00:59:11 UTC 2021 , Edited by admin on Mon Jun 28 00:59:11 UTC 2021
PRIMARY RxNorm
PUBCHEM
6918011
Created by admin on Mon Jun 28 00:59:11 UTC 2021 , Edited by admin on Mon Jun 28 00:59:11 UTC 2021
PRIMARY
INN
6649
Created by admin on Mon Jun 28 00:59:11 UTC 2021 , Edited by admin on Mon Jun 28 00:59:11 UTC 2021
PRIMARY
MERCK INDEX
M6682
Created by admin on Mon Jun 28 00:59:11 UTC 2021 , Edited by admin on Mon Jun 28 00:59:11 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL1201185
Created by admin on Mon Jun 28 00:59:11 UTC 2021 , Edited by admin on Mon Jun 28 00:59:11 UTC 2021
PRIMARY
EVMPD
SUB08402MIG
Created by admin on Mon Jun 28 00:59:11 UTC 2021 , Edited by admin on Mon Jun 28 00:59:11 UTC 2021
PRIMARY
DRUG BANK
DB06791
Created by admin on Mon Jun 28 00:59:11 UTC 2021 , Edited by admin on Mon Jun 28 00:59:11 UTC 2021
PRIMARY
NCI_THESAURUS
C1523
Created by admin on Mon Jun 28 00:59:11 UTC 2021 , Edited by admin on Mon Jun 28 00:59:11 UTC 2021
PRIMARY
FDA UNII
0G3DE8943Y
Created by admin on Mon Jun 28 00:59:11 UTC 2021 , Edited by admin on Mon Jun 28 00:59:11 UTC 2021
PRIMARY
DRUG CENTRAL
1546
Created by admin on Mon Jun 28 00:59:11 UTC 2021 , Edited by admin on Mon Jun 28 00:59:11 UTC 2021
PRIMARY
IUPHAR
2031
Created by admin on Mon Jun 28 00:59:11 UTC 2021 , Edited by admin on Mon Jun 28 00:59:11 UTC 2021
PRIMARY
CAS
108736-35-2
Created by admin on Mon Jun 28 00:59:11 UTC 2021 , Edited by admin on Mon Jun 28 00:59:11 UTC 2021
PRIMARY
LACTMED
Lanreotide
Created by admin on Mon Jun 28 00:59:11 UTC 2021 , Edited by admin on Mon Jun 28 00:59:11 UTC 2021
PRIMARY